FM OCTOBER 2018 ISSUE - digital edition

much pain. Buttonhole needle
method is not only pain free; it
is safer and easier for dialysis
patients. Patients undergoing
dialysis through this method
have reported reduction of
pain more than 95 per cent
compared with the previous
method.
NephroPlus has 128 centres
currently in 82 cities across 18
states in India.
Novaerus launches
plasma air
purifier in India
Novaerus, an Irish company
specializing in non-chemical
air disinfection, launched the
Defend 1050 in India.
Defend 1050 is a portable,
easy to use device for rapid
disinfection and purification
of the air in large spaces and
high-risk situations such as
operating-theatres, ICUs,
IVF labs, emergency
and waiting rooms, and
construction zones.
Defend 1050 uses patented
dielectric-barrier discharge
(DBD) ultra-low energy plasma
technology. It utilises specifically
designed multi-stage pre-filters,
HEFA filters and carbon filter
systems to reduce infection,
absorb odours, neutralize
volatile organic compounds
(VOCs), and trap particulate as
small as 0.3µm.
“With time, we have seen
a high contamination rate
in the air, which is resulting
toin an alarming increase in
airborne diseases and causing
adverse results to human
health. The plasma technology
Kleresca launches new biophotonic treatment
Kleresca has released a new biophotonic
technology for the treatment of rosacea.
The treatment uses fluorescent light
energy to stimulate the skin’s own repair
mechanisms through photobiomodulation.
The system consists of a patented,
multi-LED Kleresca lamp designed with
specific, pre-programmed wavelength
settings and a specially formulated
photoconverter gel. Chromophores in the
gel convert light waves from the lamp
into dynamic, pulsing fluorescent energy
that stimulates the skin’s own repair
mechanisms. The treatment is non-invasive
and generally perceived as comfortable
even to rosacea patients with enhanced skin
sensitivity.
brought by Novaerus has been
studied by NASA that has
shown how the technology is
an answer to this crisis,” said
Una Ni Raghallaigh, Business
Development Director, EMEAA
region for Novaerus Inc while
launching Defend 1050 at ISAR
(Indian Society for Assisted
Reproduction) conference
organized in Aurangabad,
recently.
Roche's
diagnostic test
for NSCLC
The US FDA has approved
Roche’s cobas EGFR
Mutation Test v2 as a
companion diagnostic test
(CDx) with gefitinib (Iressa).
Gefitinib is a targeted
monotherapy for the treatment
of patients with advanced or
metastatic epidermal growth
factor receptor (EGFR) exon 19
deletions or exon 21 (L858R)
substitution mutation-positive
NSCLC. Iressa acts by inhibiting
the tyrosine kinase enzyme in
the EGFR, thus inhibiting the
transmission of signals involved
in the growth and spread of
tumours.
A CDx test provides
information that is essential for
the safe and effective use of
a corresponding therapeutic
product. Clinical studies have
demonstrated that patients
diagnosed with NSCLC who test
positive for defined mutations
of EGFR gene benefit from
tyrosine kinase inhibitor (TKI)
therapies.
The treatment for rosacea is now available
to patients through aesthetic clinics across 10
markets including Denmark, UK, France, Spain,
Italy, Germany, Belgium, Norway, Australia and
Switzerland.
Apart from reducing inflammation, the
in-clinic treatment lowers the presence
of papules and pustules; cuts down
erythema and blushing by improving
microvascularisation; mitigates the overall
stress level of the skin, thereby reducing the
feeling of burning and stinging and induces a
healing response.
The Kleresca biophotonic system has
been available on the market since 2014. The
company recently obtained own CE-mark on
all its products.
The cobas EGFR Mutation
Test v2 is currently the only
FDA-approved diagnostic test
for NSCLC using liquid biopsy.
EGFR testing in plasma offers a
non-invasive option for patients
using a simple blood draw for
those who are not eligible for a
tissue biopsy.
The cobas EGFR Mutation
Test v2 is a real-time
polymerase chain reaction
(PCR) test for the qualitative
detection of 42 defined
mutations of the EGFR gene in
exons 18-21, including L858R,
exon 19 deletions, and T790M
mutations.
Clinical studies such as
AURA, AURA2, FLAURA,
ENSURE, EURTAC, and
FASTACT2, have demonstrated
the reliability of the cobas EGFR
Mutation Test v2, Roche said.
84 / FUTURE MEDICINE / OCTOBER 2018